Ouch, Invion…

Wow! Some days I just can’t get the timing of information and commentary right. No sooner had I posted on Invion (ASX : IVX), commenting on their lousy Lupus data announcement, then they “released the hounds” on their private placement. I suppose given the trading halt, this was anticipated and so yes, I am feeling like…

Keeping the flame alive…

Today, once again, Novogen announced that it has filed a couple of patents. Not received a notice of allowance or won an opposition or anything of commercial significance, but you know, just paperwork. Well done to Andrew Heaton and the team for getting some cunning new technology put down on the page¬†– and especially a…

The Patrys Porkpie

Notwithstanding my prior half-hearted dig at QLD and WA-based biopharma companies, one of the most underwhelming companies in the Australian life-sciences scene is right here in my own backyard – Patrys (ASX : PAB). This is a company that has had an illustrious history of underachievement,  wasteful dissipation of shareholder capital and management team largesse.…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…